US EditionPhrontline Biopharma Announces First Patient Dosed in Phase 1 Clinical ...
- Phrontline Biopharma has announced that the first patient has been successfully dosed in its Phase 1 clinical trial of TJ101, targeting EGFR/B7-H3 with proprietary technology.
- The trial will assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TJ101 across various solid tumors.
- Zhaoyuan 'Tony' Chen, CEO, stated that this milestone advances their mission to deliver innovative ADC therapies and validates their ADC platform.
- The pipeline also includes multiple early-stage ADC assets targeting significant tumor antigens, aiming to change oncology standards of care.
59 Articles
59 Articles
The Berkshire Eagle
Phrontline Biopharma Announces First Patient Dosed in Phase 1 Clinical Trial of TJ101
SHANGHAI and SUZHOU, China, Sept. 14, 2025 /PRNewswire/ -- Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), today announced that the first patient has been successfully dosed in its Phase 1 clinical trial of…
Phrontline TJ101 Phase One Trial 2025 Doses First Patient
SHANGHAI and SUZHOU, China, Sept. 15, 2025 /PRNewswire/ -- Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), today announced that the first patient has been successfully dosed in its Phase 1 clinical trial of TJ101, the company's lead asset targeting EGFR/B7-H3 with a proprietary linker-drug technology. "This is a critical milestone for Phrontline as we advance our mission…
Coverage Details
Bias Distribution
- 61% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
